Christopher P. Boone has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world data and health informatics and its ability to radically transform the U.S. health care delivery system from a healthcare quality and clinical research perspective. Boone currently serves as the Vice President and Global Medical Epidemiology and Big Data Analysis Lead at Pfizer, an adjunct professor at New York University’s Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Most recently, he served as the Vice President of Real-World Data & Analytics at Pfizer. Boone has been recognized as a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 in Minority Health Honoree by the National Minority Quality Forum.
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informing for the process from discovery to new indications, clinical trial design and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE data to better understand the patient populations using their drugs and the respective outcomes and to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.